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Abstract
Background: The integrity of the brain histaminergic system is necessary for the unfolding of homeostatic and cognitive 
processes through the recruitment of alternative circuits with distinct temporal patterns. We recently demonstrated that the 
fat-sensing lipid mediator oleoylethanolamide indirectly activates histaminergic neurons to exerts its hypophagic effects. 
The present experiments investigated whether histaminergic neurotransmission is necessary also for the modulation of 
emotional memory induced by oleoylethanolamide in a contextual fear conditioning paradigm.
Methods: We examined the acute effect of i.p. administration of oleoylethanolamide immediately posttraining in the contextual 
fear conditioning test. Retention test was performed 72 hours after training. To test the participation of the brain histaminergic system 
in the cognitive effect of oleoylethanolamide, we depleted rats of brain histamine with an i.c.v. injection of alpha-fluoromethylhistidine 
(a suicide inhibitor of histidine decarboxylase) or bilateral intra-amygdala infusions of histamine H1 or H2 receptor antagonists. 
We also examined the effect of oleoylethanolamide on histamine release in the amygdala using in vivo microdialysis.
Results: Posttraining administration of oleoylethanolamide enhanced freezing time at retention. This effect was blocked by 
both i.c.v. infusions of alpha-fluoromethylhistidine or by intra-amygdala infusions of either pyrilamine or zolantidine (H1 
and H2 receptor antagonists, respectively). Microdialysis experiments showed that oleoylethanolamide increased histamine 
release from the amygdala of freely moving rats.
Conclusions: Our results suggest that activation of the histaminergic system in the amygdala has a “permissive” role on the 
memory-enhancing effects of oleoylethanolamide. Hence, targeting the H1 and H2 receptors may modify the expression of 
emotional memory and reduce dysfunctional aversive memories as found in phobias and posttraumatic stress disorder.
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Introduction
Good memory consolidation of fear tasks requires emotional 
arousal and the engagement of the basolateral amygdala (BLA) 
(Izquierdo et al., 2016). Emotionally relevant experiences activate 
the histaminergic system (Contreras et al., 2016) that is crucial 
for the consolidation, retrieval, and extinction of such memo-
ries with different anatomical and temporal patterns (Fiorenza 
et al., 2012; Benetti et al., 2015; Fabbri et al., 2016). In particular, 
activation of histamine H1 or H2 receptors in the BLA (but also in 
the hippocampus, infralimbic, and ventromedial prefrontal cor-
teces) facilitates memory consolidation of inhibitory avoidance 
and contextual fear conditioning, whereas their specific antago-
nists have an opposite effect in the consolidation of different 
tasks (Cangioli et al., 2002; Giovannini et al., 2003; Silva et al., 
2006; Benetti and Izquierdo 2013).
The tuberomamillary nucleus (TMN) in the posterior hypo-
thalamus is the only source of histaminergic fibers that reaches 
virtually all brain regions (Panula et al., 1989); consequently, the 
brain histaminergic system regulates several brain functions, 
including alertness (Takahashi et  al., 2006) and food intake 
(Provensi et al., 2015). In this respect, we recently showed that 
a small group of histaminergic neurons in the TMN respond to 
the peripheral administration of oleoylethanolamide (OEA, a 
dietary fat-induced satiety factor) (Rodriguez de Fonseca et al., 
2001) with increased activity, as shown by enhanced expres-
sion of the early gene c-fos, and presumably these neurons 
mediate, at least in part, the hypophagic effect of OEA (Provensi 
et al., 2014). We found that in mice deficient of the histamine 
synthesizing enzyme histidine decarboxylase (HDC), or acutely 
depleted of histamine by i.c.v. infusions of the HDC blocker 
α-fluoromethylhistidine (α-FMHis) (Garbarg et  al. 1980), the 
effect of exogenously administered OEA was significantly atten-
uated (Provensi et al., 2014).
Exogenous administration of OEA after behavioral training 
was found to improve memory retention in the inhibitory avoid-
ance task, an effect that requires the activation of noradren-
ergic neurotransmission in the BLA (Campolongo et al., 2009). 
Rats’ cognitive performance produced by OEA is mimicked by 
the peripheral administration of agonists of the peroxisome-
proliferator-activated receptor-alpha (PPAR-α; Campolongo et 
al., 2009), where OEA acts as an endogenous high-affinity ago-
nist (Fu et al. 2003). Physiologically, newly formed OEA in entero-
cytes binds to PPAR-α that in turn activate sensory fibers of the 
vagus nerve with an as-yet-unknown mechanism (Rodríguez de 
Fonseca et al., 2001) to convey information to the nucleus tractus 
solitarius (NTS) in the hindbrain and from here to other brain 
regions (for review, see Piomelli, 2013). We therefore speculated 
that OEA might modulate emotional memory in another aver-
sive learning paradigm, the contextual fear conditioning test, 
and that histaminergic neurotransmission in the BLA is neces-
sary for the cognitive effect of OEA. In contextual fear condition-
ing, animals learn to associate the context (the training box) with 
a punishment (footshocks), and upon reexposure to the same 
context they display a freezing behavior, that is, a generalized 
immobility caused by a generalized tonic response. In inhibi-
tory avoidance, on the other hand, animals learn to refrain from 
stepping into a compartment where they previously received a 
footshock, but they are not refrained from moving, nor do they 
behave in any way passively. Both tests induce emotional arousal 
and require activation of the BLA, but different circuits and/or 
cellular machineries may be engaged at different times during 
memorization (Phelps et al., 2014; Izquierdo et al., 2016). Here 
we adopted a contextual fear conditioning paradigm in which 
rats were administered OEA, received intra-BLA compounds to 
manipulate the histaminergic system immediately after train-
ing, and were then reexposed to the threatening context 72 
hours later (Benetti et al., 2013) when all drugs presumably have 
been metabolized. We also measured histamine release from 
the BLA of freely moving rats following OEA administration, as 
a putative neurochemical correlate of the cognitive effects. Our 
findings revealed that the cognitive effects of OEA are blunted 
in rats with impaired histamine neurotransmission. We discuss 
our results in terms of a “permissive” role of brain histamine on 
the memory-enhancing effects of OEA that may bear relevance 
in the treatment of dysfunctional aversive memories as found 
in phobias and PTSD.
Materials and Methods
Animals and Drugs
Male Wistar rats (3 months old, 300–330 g) purchased from 
Envigo (Bresso, Italy) were housed in the animal facility of 
Ce.S.A.L (Università di Firenze) in a temperature-controlled 
room (22 ± 1°C) with a 12-h-light/dark cycle (light on 7:00 am to 
7:00 pm), at a constant temperature and humidity with stand-
ard diet (4RF21; Mucedola s.r.l., Milan, Italy) and freely available 
water. All procedures were conducted in accordance with the 
Council Directive of the European Community (2010/63/EU) of 
the Decreto Legislativo Italiano 26 (13/03/2014) and National 
Institutes of Health guidelines on animal care and were 
approved by veterinarian supervision.
Alpha-FMHis was synthesized at Johnson & Johnson 
Laboratories (kind gift of Dr. Nicholas Carruthers), pyrilamine 
was purchased from Sigma-Aldrich (UK), and zolantadine and 
OEA from Tocris Bioscience (UK). OEA was dissolved in saline/
polyethylene glycol/Tween80 (90/5/5, v/v), whereas zolantidine 
Significance Statement
The amygdala elaborates emotionally salient stimuli to provide the appropriate information to be memorized for adequate 
behavioral responses. Histaminergic neurons have important modulatory influences on memory formation; H1 and H2 histamine 
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that the brain histaminergic system has a permissive role for the unfolding of the memory-enhancing effects of oleoyletha-
nolamide (OEA). OEA, a lipid mediator that is released following the ingestion of fat, when administered posttraining in rats 
induced and exaggerated emotional response in the contextual fear conditioning paradigm that was abrogated by the inhibition 
of histaminergic neurotransmission or the local blockade of either H1 or H2 receptors in the BLA. Hence, targeting these receptors 
with classical, clinically approved antihistamines may modify the expression of emotional memory and reduce dysfunctional 
aversive memories as found in phobias and posttraumatic stress disorder.
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and pyrilamine were dissolved in saline. All other reagents 
and solvents were of HPLC grade or the highest grade avail-
able (Sigma).
Behavioral Experiments: Surgery
One week after arrival, rats were anaesthetized (75 mg/kg keta-
mine plus 10 mg/kg xylazine) and placed on a stereotaxic frame 
(Stellar; Stoeling, Co., Wood Dale, IL). A stainless-steel cannula 
(22 gauge) was implanted in the lateral ventricle and fixed to the 
skull by using dental cement according to the following coor-
dinates (Paxinos and Watson, 1998) in mm: AP = −0.9; L = −1.5; 
DV = −2.6 and used for α-FMHis/saline administration. Rats were 
also implanted bilaterally with 22-gauge guide cannulae 1 mm 
above the BLA according to the following coordinates from 
bregma (Paxinos and Watson, 1989) in mm: AP = −2.8; L = ±4.9; 
DV  =  +7.6. Animals were allowed 7  days to recover from sur-
gery before behavioral procedures and were handled once daily 
before the experimental day.
Infusion Procedure and Experimental Groups
At the time of drug microinfusions, the animals were gently 
restrained by hand, and the injection needle (30 gauge) was fit-
ted tightly into the guides, extending 1 mm from the tip of the 
guide cannulae. The injection needle was connected to a 10-μL 
Hamilton microsyringe, and the infusions were performed at a 
rate of 0.5 μL/30  s. The infusion cannula was left in place for 
an additional 60 seconds to minimize backflow. The entire bilat-
eral infusion procedure took approximately 90 seconds. Alpha-
FMHis (5 mM, 1 µL) was infused i.c.v. 24 hours before contextual 
fear training, and controls received equal volumes of sterile 
saline. Zolantidine (0.1 μM, 0.5 µL side) or pyrilamine (0.9 μM, 
0.5 µL side) were infused intra-BLA bilaterally immediately after 
training. OEA (10 mg/kg) was injected i.p. 10 minutes after fear 
conditioning, while controls received equivalent volumes of 
vehicle.
Contextual Fear Conditioning
Contextual fear conditioning was induced in a Skinner box 
module (29  ×  31  ×  26  cm, Modular Operant Cage; Coulbourn 
Instruments Inc.), equipped with a grid floor connected to a 
shock-delivery apparatus (Modular Operant Cage/Grid Floor 
Shocker E13-08; Coulbourn Instruments) and placed in an 
acoustically insulated room at 20 ± 1°C. The number of the elec-
tric shocks and the inter-shock interval duration was predeter-
mined by a stimulus programming device (Scatola di comando 
Arco 2340, Italy). Illumination inside the room was 60 lux. The rat 
was left undisturbed for 3 minutes and subsequently six, 1-sec-
onds 0.8-mA electric footshocks were administered at 30-sec-
ond intervals. The footshock intensity was chosen according 
to previous published data from our laboratory (Benetti et  al., 
2013). This is a strong enough footshock to guarantee retention 
at 72 hours postacquisition without inducing generalization 
(Baldi et al., 2004). The rat was removed 2 minutes after the end 
of the stimulation, therefore spending a total time of 8 minutes 
inside the conditioning apparatus.
Freezing Measurement
Seventy-two hours after conditioning, rats were again placed 
inside the conditioning apparatus in the soundproof room 
and left undisturbed for 6 minutes. The rats’ behavior was 
recorded by means of a closed-circuit television system by 
an experimenter unaware of the animal’s treatment. Freezing 
was defined as the complete absence of somatic motility, 
with the exception of respiratory movements. Measurements 
were performed with a stopwatch by personnel unaware of 
the experimental group each animal belonged to. Total cumu-
lated freezing time (i.e., total seconds spent freezing during 
each 6-minute period) was calculated and results expressed in 
seconds of freezing time. All behavioral tests were performed 
between 10:00 am and 12:00 pm to avoid interference with the 
circadian rhythm (Kamin, 1957).
Microdialysis Experiments
Surgery
Rats were anesthetized with (75  mg/kg ketamine plus 10  mg/
kg xylazine) and positioned in a stereotaxic frame (Stellar, 
Stoelting Co.). One guide cannula (MAB 4.15.IC, Microbiotech) 
was implanted according to the following coordinates from 
bregma (Paxinos and Watson, 1988, in mm): paraventricular 
nucleus (PVN) AP = -1.9, L = -0.5, DV = +7.5; ventromedial hypo-
thalamus (VMH), AP = -2.6; L = -0.5; DV = +9.0; BLA, AP  =  -2.8, 
L =  -4.8, DV = +7.8. A surgical screw served as an anchor, and 
the cannulae were fixed to the skull with acrylic dental cement. 
The animals were then housed one per cage and left to recover.
In Vivo Microdialysis Experiments
The microdialysis experiments were performed as previously 
described (Munari et  al., 2013). Briefly, 48  h after surgery, the 
stylet was removed from the guide cannula, and the microdi-
alysis probes (1 mm, molecular weight cut-off = 6000 Da, MAB 
4.15.1.PES Microbiotech) were inserted. Probes were perfused 
with Ringer’s solution (in mM: NaCl, 147; CaCl2, 1.2; and KCl, 4.0 
at pH = 7.0) at a flow rate of 2 μL/min using a microperfusion 
pump (Carnegie Medicine; Mod CMA/100). After 120-min equi-
libration, the sample collection started at 15-minute intervals. 
Spontaneous release was defined as the average value of the 
five 15-minute fractions collected during 75 minutes of perfu-
sion with Ringer’s solution prior to OEA 10 mg/kg systemic (i.p.) 
treatment. All subsequent fractions were expressed as percent-
age of this value. To prevent degradation of histamine, 1.5 mL of 
5 mM HCl was added to each sample. The dialysates were kept 
at -80°C until analysis.
Determination of Histamine
Histamine contents in the dialysates were determined by HPLC-
fluorometry (Munari et al., 2013). In brief, the column (Hypersil 
ODS, 3 µm, 2.1 × 100 mm; Thermo Fisher Scientific, Waltham, MA) 
was eluted with 0.25 M potassium dihydrogen phosphate con-
taining 5% octanesulfonic acid (Sigma-Aldrich, St. Louis, MO) 
at a flow rate of 0.4 mL/min. The eluate from the column was 
mixed first with 0.1% o-phthalaldehyde solution at a flow rate 
of 0.1  mL/min and then to a solution containing 4 M sodium 
hydroxide and 0.2 M boric acid (flow rate, 0.137 mL/min) to adjust 
the reaction mixture to pH 12.5. The reaction took place at 45°C. 
Then 17% orthophosphoric acid was added to the solution (flow 
rate, 0.137 mL/min) to reach a final reaction mixture at pH 3. The 
fluorescent intensity was measured with a spectrofluorometer 
(series 1100; Agilent, Waldbronn, Germany) at 450 nm with exci-
tation at 360 nm. The sensitivity limit was 10 fmol and the sig-
nal/noise ratio was >3. Histamine levels in the dialysate samples 
were calculated as fmol/30 min and were not corrected for probe 
recovery (about 40%).
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Histology
The placement of microdialysis membranes and infusion can-
nulae was verified postmortem (Figure 3A). Rats were overdosed 
with chloral hydrate and the brains removed and stored in 10% 
formalin for 10  days. Forty-μm sections were sliced on a cry-
ostat, mounted on gelatine-coated slides, and then stained with 
cresyl violet for light microscopic observation. Data from rats in 
which the membranes were not correctly positioned were dis-
carded (<5%).
Statistical Analysis
All values are expressed as means ± SEM, and the number of rats 
used in each experiment is also indicated. The presence of sig-
nificant treatment effects was determined by a Student’s t test 
or a 1-way ANOVA followed by Newmann Keuls’ MCT test, as 
appropriate. For all statistical tests, P < .05 was considered signif-
icant. In the figures and figure legends of microdialysis experi-
ments, we reported only the significant differences vs the last 
sample before drug treatment for clarity purposes.
Results
In a first set of experiments, we evaluated the effect of OEA (10 
mg/kg i.p., a dose that does not change motility in the open 
field, nor anxiety-like responses) (Campolongo et al., 2009) 
administered within 10 minutes of contextual fear condition-
ing in satiated rats. Controls received an equivalent volume of 
vehicle. Retention test was carried out 72 hours after training. 
As shown in Figure 1, an unpaired Student’s t test showed that 
animals given OEA displayed a significant increase of time spent 
freezing compared with vehicle-treated rats (P < .01). To evalu-
ate the role of the central histaminergic system in the cogni-
tive effect of OEA, we infused the HDC inhibitor α-FMHis i.c.v. 
24 hours prior to fear conditioning. We previously showed that 
administration of α-FMHis quickly suppressed baseline and 
histamine H3 receptor antagonist-evoked release of histamine 
from the TMN of freely moving rats (Benetti et al., 2015), as 180 
minutes after injection, histamine release values decreased 
below the sensitivity of the method. OEA (10 mg/kg i.p.) was 
injected within 10 minutes after fear conditioning. Controls 
received saline i.c.v. and vehicle i.p. One-way ANOVA revealed 
a statistical difference across experimental groups (F3,45 = 6.756; 
P < .001) (Figure 2). Posthoc analysis with Newman-Keuls MCT 
showed that OEA increased the freezing time at retention test 
with respect to vehicle-treated rats receiving i.c.v. infusion of 
saline (P < .05). However, the OEA-elicited potentiation of freez-
ing was abolished in brain histamine-depleted animals (P < .01) 
(Figure 2). Hence, the treatment with α-FMHis 24 hours prior to 
the test prevented the effect of OEA, indicating that the integrity 
of the central histaminergic system is necessary for the effects 
of OEA on memory consolidation. The freezing time of rats given 
vehicle i.p. and of those receiving α-FMHis or saline i.c.v. did not 
differ significantly at retention, thus indicating that all animals 
formed a memory trace of the training experience. The fact that 
histamine release is restored to control levels about 3 days after 
treatment with α-FMHis (Benetti et al., 2015) may explain this 
result.
We then tested the hypothesis that histamine release and 
histamine receptor activation in the BLA might be relevant for 
the cognitive effect of OEA. We blocked H1 or H2 receptors in the 
BLA with local, bilateral infusions (0.5 µL) of the selective antag-
onists pyrilamine (0.9 μM) or zolantidine (0.1 μM), respectively, 
immediately prior to the administration of OEA. The concen-
trations used were those employed in previous studies (Benetti 
et  al., 2013). Controls received comparable volumes of saline 
intra-BLA and of vehicle i.p. The results are shown in Figure 3B. 
One-way ANOVA showed significant differences among exper-
imental groups (F5,64  =  8.436; P < .0001). Rats that received OEA 
i.p. and saline intra-BLA froze for a significantly longer time at 
retention compared with saline-/vehicle-treated rats (P < .05) in 
a comparable manner to the control groups in Figures 1 and 2. 
However, when either H1 or H2 receptors were blocked, OEA 
administration did not increase the freezing time (P < .001). 
Freezing time of rats that received vehicle i.p. and pyrilamine or 
zolantidine in the BLA was not significantly different from the 
freezing time of saline-/vehicle-treated rats (Figure 3B).
Given that OEA requires the integrity of the histaminergic 
neurotransmission in the BLA to exert its cognitive effects, we 
then investigated if OEA changes histamine release from the BLA 
by means of the microdialysis technique in freely moving rats. 
As shown in Figure 4A, i.p. injections of 10 mg/kg OEA induced a 
transient, but significant increase of histamine release from the 
BLA that reached a peak value approximately 30 minutes after 
the administration of OEA (F12,61 = 5.336; P < .001); it was sustained 
for the following 30 minutes and then returned to baseline level. 
To understand if the histaminergic system responds to OEA 
with a generalized increased activity throughout the brain, we 
also measured histamine levels in the VMH and PVN. We chose 
Figure 1. Postacquisition injections of oleoylethanolamide (OEA) affect contex-
tual fear memory consolidation. The schematic drawing shows the sequence 
of procedures and treatment administrations. OEA (10 mg/kg) or vehicle (VEH) 
were injected i.p.  10 minutes after contextual fear conditioning. All animals 
were tested for fear retention 72 hours after conditioning. Bars represent mean 
values ± SEM of 8 to 10 rats/group; **P < .01; unpaired t test.
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these 2 brain areas as they are innervated by histamine fibers 
and express high density of H1 receptors that regulate feeding 
behavior and obesity in rodents (Masaki and Yoshimatsu, 2006). 
Another reason is that we previously showed that systemic 
administration of OEA in hungry mice activates oxytocic neu-
rons in the PVN by engaging histaminergic neurotransmission 
in this hypothalamic nucleus (Provensi et  al., 2014). However, 
we found that histamine release was not changed significantly 
after OEA i.p. injection in either nucleus (Figure 4B-C). Rather, a 
trend towards decreased histamine release was observed in the 
PVN, although it did not reach significance.
Discussion
Emotional arousal enhances consolidation of memory traces, 
a homeostatic response of our organism that is modulated by 
stress hormones (McGaugh and Roozendaal, 2002). There is 
extensive evidence derived from observations in both experi-
mental animals and humans that the amygdala is indispensable 
to enable the acquisition and retention of lasting memories of 
emotional experiences. The compelling evidence led McGaugh 
and his collaborators (McGaugh et  al., 2004)  to propose that 
the activation of the BLA is fundamental in the establishment 
of an arousal state triggered by fear (as unconsciously occurs 
in humans, LeDoux, 2014) and that arousal is a major compo-
nent in the establishment of posttraining memory consolida-
tion. The elegant work of Campolongo and coauthors (2009) 
demonstrated that there are unsuspected players in addition 
to stress hormones (i.e., adrenaline and corticosteroids) that 
affect memory consolidation of fearful stimuli, namely the sati-
ety factor OEA, normally secreted by the intestine after a fatty 
meal. Exogenous OEA at the concentration used here does not 
readily pass the blood brain barrier (Campolongo et  al., 2009). 
By activating peripheral PPAR-α it engages the vagus nerve and 
activates the NTS that in turn provides the amygdala, together 
with the locus coeruleus (LC), with a dense supply of norepi-
nephrine. Stimulation of NTS (Clayton et al., 2000) or LC (Sara, 
2009; Rosa et  al., 2013)  contributes to memory processing by 
influencing noradrenergic neurotransmission in the amygdala. 
OEA enhances memory consolidation of the inhibitory avoid-
ance task by inducing noradrenergic activation of BLA neurons 
(Campolongo et al., 2009). The cognitive effects of OEA are lost in 
PPAR-α mice and in rats that received intra-NTS infusion of lido-
caine, further substantiating the hypothesis that vagal afferents 
contribute to the cognitive effects of OEA (Campolongo et  al., 
2009). Our present results show that OEA increases memory 
expression of another aversively motivated task, contextual fear 
conditioning, by eliciting histaminergic neurotransmission in 
the BLA. Accordingly, both depletion of releasable histamine in 
the brain with α-FMHis that blocks HDC, and intra-BLA infusion 
of histaminergic antagonists prevent the freezing-enhancing 
effects of OEA. The concept of several neurotransmitter sys-
tems contributing to emotional memory consolidation within 
the same brain region is indisputable (Izquierdo et  al., 1992; 
McGaugh 2004; Izquierdo et al., 2016). We think that the emo-
tional arousal that is generally considered indispensable for 
good memory consolidation of fear tasks is provided by both 
Figure 2. Effect of histamine neurotransmission on oleoylethanolamide (OEA)-
induced freezing enhancement. The schematic drawing shows the sequence of 
procedures and treatment administrations. Latencies of α-FMHis groups did not 
significantly differ from controls. Data are expressed as means ± SEM of 10 to 
14 animals for each group; ANOVA and Newman-Keuls posthoc test, *P < .05 vs 
saline (SAL) controls. ## P < .01 vs OEA/SAL.
Figure  3. Effect of histamine receptor antagonism on oleoylethanolamide 
(OEA)-induced freezing enhancement. (A) Schematic diagram and photomicro-
graphs showing the position of the cannulae. The injection needle protruded 
1 mm below the tip of the cannulae. (B) Rats received bilateral intra-basolateral 
amygdala (BLA) infusions of zolantidine (ZOL), pyrilamine (PYR), or vehicle, and 
OEA or vehicle i.p. immediately after training. Data are expressed as means ± 
SEM of 9 to 14 animals for each group; ANOVA and Newman-Keuls’ posthoc test, 
**P < .01 vs SAL/VEH controls; ###P < .001 vs SAL/OEA.
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the noradrenergic and histaminergic transmission in the BLA. 
We recently observed that OEA elicits NTS activation in HDC-KO 
mice (hence unable to synthesize histamine) as well as in wild-
type littermates (Umehara et al., 2016). Therefore, the regulatory 
action of histamine on the cerebral pathways triggered by OEA 
is most likely downstream of the NTS. A prudent interpretation 
of our results is that histamine released in the amygdala or in 
the LC (Korotkova et al., 2005; Lee et al., 2005) gates the effects 
of noradrenaline on BLA neurons, hence blocking either neu-
rotransmitter within the BLA would lead to similar behavioral 
outcomes.
We previously documented that histamine neurotransmis-
sion in diverse brain areas is necessary for the consolidation of 
contextual fear memory, as infusions of H3 receptors antago-
nists in the BLA decrease the freezing time of contextual fear-
conditioned rats and decrease acetylcholine release in the same 
region (Passani et al., 2001). Also, in the nucleus basalis magno-
cellularis memory improvement for contextual fear condition-
ing requires the activation of H2 receptors (Benetti et al., 2013), 
presumably by controlling the activity of the amygdalopetal 
cholinergic pathway (Power and McGaugh 2002). It is relatively 
surprising that both H1 and H2 receptor antagonists produce 
the same results. The arrangement of these receptors on BLA 
neurons is not known, and explanations may only be specula-
tive. Jiang et al. (2005) recorded intracellular excitatory postsyn-
aptic potentials from BLA neurons ex vivo in the presence of 
histamine and described the opposite responses of 2 neuronal 
populations with decreased or increased excitatory postsynap-
tic potential amplitude. The authors fell short of demonstrating 
what postsynaptic histamine receptors may partake in these 
effects; hence, it is not known if H1 and H2 receptors are on differ-
ent cell populations. In the vascular system, H1 and H2 receptors 
may work synergistically via activation of common intracellular 
pathways (Panula et al., 2015), which is a mechanism that may 
also occur in neurons. It is plausible that when strong aversive 
stimuli are used, as in our paradigm, all histaminergic inputs to 
the BLA need to be blocked to prevent freezing-enhancing com-
pounds such as OEA to exert their effect.
Figure 4. Histamine extraneuronal levels were measured in fractions collected every 15 minutes. Baseline values were determined from the average of 5 samples 
preceding oleoylethanolamide (OEA) i.p. injection. OEA significantly increased the extraneuronal levels of histamine in the basolateral amygdala (BLA), but not in the 
paraventricular nucleus (PVN) nor the ventromedial hypothalamus (VMH). The mean basal extraneuronal level of histamine was (fmol/15 min) 22.8 ± 23.1 in the BLA 
(n = 5), 118.5 ± 74.2 in the PVN (n = 6), and 47.4 ± 24.4 in the VMH (n = 6). ANOVA and Newman-Keuls’ posthoc test, *P < .05 vs baseline levels.
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Of interest, BLA infusion of the H1 or H2 receptor antagonists 
did not affect the expression of baseline fear memory tested 
72 hours after training; rather these treatments prevented the 
freezing enhancement induced by OEA. These results are in 
good agreement with our previous observations using the same 
behavioral protocol that neither pyrilamine nor zolantidine 
changed freezing responses when administered in the NBM 
(Benetti et al., 2013) but prevented the increased expression of 
fear memory induced by an H3 receptor antagonist.
Rats depleted of histamine with i.c.v. injections of α-FMHis 
had a behavior comparable with controls treated with saline, 
but α-FMHis prevented the effect of OEA on freezing time. 
We explain this considering that the effect of α-FMHis lasts 
approximately 3 days (Benetti et al., 2015); therefore at the time 
of the retention test (4 days after α-FMHis infusion) histamine 
neurotransmission should be restored to normal levels, which 
presumably allows the expression of the memory trace. These 
results are in agreement with what we observed using another 
behavioral paradigm, inhibitory avoidance, as the memory 
impairment induced by pretraining injections of α-FMHis lasted 
48 hours; the step-down latency returned to control levels after 
1 week (Benetti et al., 2015). Despite the well-documented differ-
ences between inhibitory avoidance, a procedure that requires 
a discriminative response, and fear conditioning, a Pavlovian 
procedure that does not require decision making (Maren, 2003; 
Tinsley et al., 2004), OEA appears to enhance the expression of 
BLA-dependent emotional memory regardless of the type of 
behavioral response and adverse situation. The microdialysis 
experiments offered one further piece of data in favor of the 
hypothesis that OEA requires the histamine neurotransmission 
in the BLA to modulate emotional responses. OEA administered 
at the same dose that increased freezing time augmented signif-
icantly histamine release from the BLA, but not from hypotha-
lamic nuclei where histaminergic and OEA signalling converge 
to regulate appetite (Provensi et al., 2014). This could be a quite 
puzzling observation, but we believe that the histaminergic sys-
tem responds to various stimuli, in this case OEA administered 
systemically, by engaging different pathways according to the 
required behavioral response. As an example, in food-restricted 
mice OEA increases c-fos expression in the PVN and supraoptic 
nucleus but not in other hypothalamic nuclei that receive hista-
minergic afferents and control eating behavior such as the VMH 
(Provensi et al., 2014) or dorsomedial hypothalamus (Umehara et 
al., 2016). In the present study, during dialysate collection sati-
ated rats are quiet or sleeping, and it is plausible that in this 
circumstance OEA does not engage histaminergic afferents to 
the PVN to regulate their activity; rather it recruits the hista-
minergic afferents to the BLA. Indeed, we believe that the TMN 
serves as a neuronal gateway that integrates hormonal, intero-
ceptive, and environmental signals to coordinate the adequate 
behavioral response. This hypothesis implies that HA neurons 
in the TMN are organized in distinct subpopulations differently 
regulated and innervating specific brain areas. There is much 
experimental evidence supporting this view (Blandina et al., 
2012; Munari et al., 2013).
What is the physiological significance of exaggerated emo-
tional response induced by OEA? The few human studies 
published so far showed that blood concentrations of N-acyl-
ethanolamides like OEA and other endocannabinoids increase 
in response to acute stress in healthy human volunteers (Dlugos 
et  al., 2012), and subjects affected by PTSD have significantly 
higher plasma concentrations of OEA (Hauer et al. 2013; Schaefer 
et  al., 2014). Despite the fact that these results are based on 
small and dis-homogeneous study groups, they may have 
pathophysiological and/or diagnostic relevance. In this respect, 
our results suggest that activation of the histaminergic system in 
the BLA has a “permissive” role on the memory enhancing effects 
of OEA. In particular, targeting the H1 or H2 receptor with classical 
clinically approved antihistamine compounds may modify the 
expression of emotional memory and reduce dysfunctional aver-
sive memories as found in phobias and PTSD.
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